Top Injectable Manufacturer in Burkina Faso – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 2 hours ago
- 10 min read
Last Updated: July 26, 2026
TL;DR: Burkina Faso is a landlocked West African market of about 24.1 million people that imports more than 90% of the medicines it consumes and has no domestic sterile injectable capacity. India is already its second-largest source of packaged medicines. The regulator is the Agence Nationale de Régulation Pharmaceutique (ANRP), created in October 2018 and ISO 9001:2015 certified; it grants a five-year Autorisation de Mise sur le Marché under UEMOA Règlement n°04/2020, with a statutory processing window of 120 to 360 days. Two things decide whether an entry works: registering as an INN generic costs 150,000 FCFA against 1,500,000 FCFA for a branded multi-source copy, and every consignment needs a Laboratoire National de Santé Publique certificate of conformity before customs clearance or market release. Farbe Firma Pvt Ltd manufactures over 100 sterile injectables at a WHO-GMP certified, ISO Class 5 facility in Gujarat, India, exports to more than 30 countries, and prepares CTD/ACTD dossiers, WHO-format CPPs and CAMEG prequalification files.
Key Takeaways
The regulator is a real agency, and it is certified. The Agence Nationale de Régulation Pharmaceutique (ANRP) was created by Décret n°2018-0861 of 5 October 2018, replacing the former DGPML, and holds ISO 9001:2015 certification obtained in 2024 with a second surveillance audit passed in May 2026. It publishes an annual calendar of homologation committee and commission sessions — file against that calendar, not against a guess.
Brand strategy has a ten-fold cost consequence. Under the published ANRP tariff, registering a product made outside UEMOA and ECOWAS costs 150,000 FCFA as an INN generic and 1,500,000 FCFA as a branded multi-source copy of a specialty, with the same 10:1 ratio applying to every major variation and every five-year renewal. A wholesale establishment licence is 1,000,000 FCFA and an import visa is 1,000 FCFA per application for up to twenty items.
The LNSP certificate is the step most exporters miss. Under Arrêté conjoint n°2003-008/MS, customs clearance and market release both require a certificate of conformity from the Laboratoire National de Santé Publique, and the annexed scope explicitly covers human medicines, infusion solutions, immune sera, vaccines and even the glass containers and rubber stoppers used for injectables. Sampling and analysis costs fall on the importer.
CAMEG is the route into public volume, and it changed status in 2024. The Centrale d'Achat des Médicaments Essentiels Génériques became a société d'État with 5 billion FCFA of capital by Décret n°2024-0448 of 17 April 2024. It is ISO 9001:2015 certified, runs roughly 30,000 m² of warehousing with a 2–8 °C cold room, ten agencies and about seventy distribution depots, and buys through an open international prequalification of suppliers with a three-year agrément, then restricted consultations among prequalified suppliers.
Introduction: Why an Injectable Manufacturer in Burkina Faso Must Meet Global Standards
Burkina Faso's public health system counts 2,732 facilities: 2,266 Centres de Santé et de Promotion Sociale at the base, 144 Centres Médicaux, 46 Centres Médicaux avec Antenne chirurgicale, ten regional hospitals and six university hospitals including CHU Yalgado Ouédraogo, CHU de Bogodogo, CHU de Tengandogo and CHU Sourou Sanou in Bobo-Dioulasso, organised across 70 health districts. It imports more than 90% of the medicines it uses, and India is already the second-largest source of its packaged-medicine imports at about US$46.4 million of a US$165 million total in 2023. For any injectable manufacturer in Burkina Faso, that combination — large structured demand, negligible local sterile production, and an established Indian supply relationship — is the commercial opening. What decides whether it converts is documentation discipline.
The clinical burden is unambiguous. Malaria drives roughly 43% of health-provider consultations; WHO estimated 8.32 million cases and 16,184 deaths for 2024, and Burkina Faso has run the High Burden to High Impact approach since November 2019. Intravenous artesunate is first-line for severe malaria in public facilities, with injectable quinine as the fallback. Maternal mortality is 242 per 100,000 live births, and national surveillance attributes about 45% of maternal deaths to external haemorrhage and 27% to hypertensive disorders — roughly 72% treatable with oxytocics, tranexamic acid and magnesium sulphate. The country sits squarely in the meningitis belt, reporting 1,495 suspected cases and 64 deaths in the closed 2026 season with ceftriaxone as the five-day case-management workhorse. Add the largest dengue epidemic ever recorded in Africa in 2023, a snakebite burden of over 114,000 envenomations in five years of which only 4% received antivenom, and 733 health facilities affected by insecurity as of August 2024, and the demand picture is both deep and urgent.
What Sets a World-Class Injectable Manufacturer in Burkina Faso Apart
The first differentiator is sterile capability that stands up to inspection. CAMEG's own supplier prequalification demands a valid GMP certificate for each proposed production site issued by the origin-country authority or an ICH or PIC/S regulator, a site master file, a quality-assurance manual, and a signed declaration accepting a GMP audit of the plant. That is a real audit exposure, not a paperwork formality, and a supplier that incurs a critical or major quality fault can only restore its standing through a pharmaceutical audit of the production site. Farbe Firma runs its Gujarat facility to WHO-GMP standards with ISO Class 5 aseptic filling under unidirectional airflow, validated sterilisation and filtration, media fills, container-closure integrity testing and a documented contamination-control strategy.
The second differentiator is knowing exactly where the Burkinabè pathway differs from its neighbours'. The Autorisation de Mise sur le Marché is governed by UEMOA Règlement n°04/2020, is valid five years, must be renewed at least 120 days before expiry, and carries a statutory processing window of no less than 120 and no more than 360 days with a clock-stop whenever ANRP requests further information. The dossier is the ECOWAS-harmonised five-module CTD, submitted on CD-ROM and paper. Module 1 must carry a WHO-format Certificate of Pharmaceutical Product, GMP compliance status from other regulators with the date of the last inspection, letters of access to the drug master file, and evidence of regulatory status in the country of origin and elsewhere; Module 3 must carry an original WHO-type GMP certificate, a valid manufacturing authorisation and the site master file. Fifty commercial samples are needed for a generic, each with at least eighteen months of remaining shelf life, from a single batch with certificates of analysis. And one criterion catches exporters by surprise: under Article 12, the Commission weighs the ex-tax wholesale price, the daily and total cost of treatment, and the number of similar multi-source products already on the market. A dossier can be refused on economic grounds.
Quality Systems Behind Every Batch We Ship to Burkina Faso
Every Farbe Firma injectable batch destined for Burkina Faso is released only after the full analytical stack is complete and reviewed. Identity, assay and related substances are determined by validated HPLC or GC methods against USP, BP, IP or EP monographs; water content by Karl Fischer for lyophilised presentations; sterility by membrane filtration or direct inoculation; bacterial endotoxins by LAL; and particulate matter, pH, osmolality, fill volume and container-closure integrity to compendial limits. That release package is not only for our own quality system — it is the evidence base the Laboratoire National de Santé Publique draws on when it samples an incoming consignment and issues the certificate of conformity without which neither customs clearance nor market release can proceed.
Behind release testing sits the quality architecture that makes those results meaningful. Stability runs on three batches under real-time and accelerated conditions per ICH Q1A with photostability per ICH Q1B, and for Burkina Faso we generate Climatic Zone IVa data in line with WHO TRS 953 Annex 2, which CAMEG explicitly requires from suppliers whose products are not WHO-prequalified. Interchangeability evidence — bioequivalence or comparative dissolution per WHO TRS 937 Annex 8 — and certificates of analysis for the three most recently released batches are part of the same package. Thermostability deserves particular attention here: Burkina Faso's own national post-partum haemorrhage guideline warns that oxytocin is not thermostable, that its labelling can be misleading and that poor-quality product circulates, while listing heat-stable carbetocin, misoprostol and tranexamic acid as requiring no cold chain. In a country where 31% of health facilities were closed or only minimally functioning as of August 2024 and convoys move under military escort, a thermostable presentation is a commercial differentiator, not a technical footnote.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Burkina Faso for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables at its WHO-GMP certified facility in Gujarat, India, and exports to over 30 countries. The portfolio spans anti-infectives, antimalarials, analgesics, anaesthetics and muscle relaxants, cardiovascular and emergency medicines, oncology support and obstetric products, in dry-powder vials, liquid ampoules, lyophilised presentations and small-volume parenterals. That maps directly onto Burkina Faso's Liste Nationale des Médicaments Essentiels 2023, which runs to 615 medicines for adults and 511 for children and references injectable presentations hundreds of times — including artesunate 60 mg and 120 mg with its separate sodium bicarbonate ampoule, oxytocin at every facility level, carbetocin and magnesium sulphate now listed down to CSPS level, and tranexamic acid from Centre Médical upward.
Our CDMO services scale from a single distributor's launch portfolio to full tender volumes. Contract and third-party manufacturing runs under the customer's brand with technology transfer, artwork development, and regulatory dossiers compiled in CTD or ACTD format, with Module 1 and all labelling in French as UEMOA Règlement 04/2020 requires. We supply WHO-format CPPs, GMP certificates issued by the competent authority, site master files, manufacturing authorisations, drug master file letters of access, batch certificates of analysis, ICH Q1A and Zone IVa stability packages, and the interchangeability data CAMEG asks for — the full set that reduces a fifteen-document non-prequalified submission to something a Burkinabè partner can actually assemble on schedule.
Buyers stay with Farbe Firma because we are candid about how the Burkinabè route really works. Placing product on the market requires a licensed établissement pharmaceutique de vente ou de distribution en gros with a personally liable pharmacien responsable; the Ordre National des Pharmaciens publishes a register of the 31 licensed wholesale and distribution establishments, and that register is your prospect list. Public volume runs through CAMEG's two-stage model: an open international prequalification producing a validated database of product and manufacturer couples, with a three-year agrément and a non-refundable dossier fee between 500,000 and 2,000,000 FCFA depending on the number of products, followed by restricted consultations among prequalified suppliers. Payment is structured as 50% within twenty days of provisional acceptance and 50% within twenty days of definitive acceptance, against a 10% performance bond. Essential generics under INN are priced exclusive of customs duties and taxes, which reflects the underlying position: customs duty on pharmaceuticals is abolished and medicines are VAT-exempt, leaving roughly 2.8% to 3.3% of CIF in statistical, community and AES levies. The real work is upstream — corridor choice among Lomé at 948 km, Tema at 1,040 km, Cotonou at 1,060 km and Abidjan at around 1,100 km with the only working rail link to Ouagadougou; a Bordereau de Suivi des Cargaisons validated before the vessel reaches the transit port; and an LNSP conformity certificate in hand before anything clears. Burkina Faso left ECOWAS on 29 January 2025 but remains a full UEMOA member — indeed it hosts the UEMOA Commission in Ouagadougou — so the AMM regime under Règlement 04/2020 is unchanged.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer that can supply Burkina Faso?
Yes. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, with ISO Class 5 aseptic filling areas, more than 100 injectable products and exports to over 30 countries. For Burkina Faso we provide the documentation the ANRP and CAMEG both require: a WHO-format Certificate of Pharmaceutical Product, an original WHO-type GMP certificate with a valid manufacturing authorisation, the site master file, drug master file letters of access, batch certificates of analysis for recent released batches, ICH Q1A stability with Climatic Zone IVa data per WHO TRS 953 Annex 2, and interchangeability evidence per WHO TRS 937 Annex 8. We also accept GMP audit of the production site, which CAMEG requires suppliers to declare in writing.
How long does registration take in Burkina Faso, and what does it cost?
The Autorisation de Mise sur le Marché is governed by UEMOA Règlement n°04/2020 and carries a statutory processing window of at least 120 days and no more than 360 days, with the clock stopping whenever ANRP requests additional information. The AMM is valid five years and renewal must be filed at least 120 days before expiry. On the published ANRP tariff for products manufactured outside UEMOA and ECOWAS, an INN generic costs 150,000 FCFA, an innovator specialty 300,000 FCFA, and a branded multi-source copy of a specialty 1,500,000 FCFA — ten times the generic rate, with the same ratio on major variations and renewals. Registering under the INN rather than a brand is therefore the single largest cost decision in the filing.
What is the LNSP certificate, and why does it matter for injectables?
The Laboratoire National de Santé Publique performs mandatory quality control on defined categories of health products before they are released for consumption, whether imported or locally made. Under Arrêté conjoint n°2003-008/MS, customs clearance and market placement can only proceed on presentation of the LNSP certificate of conformity, and the cost of samples and analyses is borne by the importer or manufacturer. Injectables are squarely in scope: human medicines, solutions for infusion, immune sera and human vaccines are all listed, and so are the glass containers and rubber, silicone or elastomer stoppers used in injectable packaging. Build the LNSP sampling and analysis step into your lead time and your landed cost from the outset.
Which injectables are in strongest demand in Burkina Faso?
Antimalarials first. Intravenous artesunate is first-line for severe malaria in public facilities, with injectable quinine where artesunate is unavailable and intramuscular artemether in private facilities equipped to treat severe cases; seasonal malaria chemoprevention now runs in all 70 health districts. Obstetric injectables come next, since haemorrhage and hypertensive disorders account for around 72% of maternal deaths — oxytocin and heat-stable carbetocin, tranexamic acid and magnesium sulphate, all on the 2023 essential medicines list with carbetocin and magnesium sulphate now available down to CSPS level. Then ceftriaxone as the meningitis-belt case-management standard on a five-day regimen, snake antivenom against a burden where only 4% of envenomation patients historically received it, intravenous fluids and crystalloids for dengue seasons, and the anaesthesia, emergency and surgical lines supporting 46 district surgical centres and 16 regional and university hospitals.
Do we need a local partner, and how do we reach public-sector volume?
A local partner is mandatory. Product can only be placed on the market through a licensed établissement pharmaceutique de vente ou de distribution en gros with a registered pharmacien responsable who is personally liable for regulatory compliance; the Ordre National des Pharmaciens publishes the register of the 31 licensed wholesale and distribution establishments. For public volume the route is CAMEG, which since April 2024 is a société d'État with 5 billion FCFA of capital and holds ISO 9001:2015 certification. It buys in two stages: an open international prequalification of suppliers, without nationality restriction, granting a three-year agrément against a non-refundable dossier fee of 500,000 to 2,000,000 FCFA depending on the number of products; then restricted consultations among prequalified suppliers. CAMEG invites primary manufacturers or their approved representatives, requires two intact commercial packs as samples for injectable ampoules and two vials with cartons for infusion solutions, and pays 50% within twenty days of provisional acceptance and 50% within twenty days of definitive acceptance against a 10% performance bond.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments